![online calcusyn online calcusyn](https://royalsocietypublishing.org/cms/asset/1956927e-243b-45e4-961a-f247ac2ce8ab/rsos202178f18.jpg)
Particularly, amplification of the neural MYC ( MYCN) oncogene, which occurs in 20–30% of all NB tumors and nearly 50% of the high- risk cases, remains a key predictor of poor outcomes. Approximately 50% of NB patients are diagnosed with high-risk disease, and despite intensive multimodal therapy options (including radiation, surgery, and chemotherapy), effective treatment for these patients remains elusive. Neuroblastoma (NB) is the most common extracranial pediatric solid tumor of neural crest origin and accounts for approximately 10% of childhood cancers and 15% of cancer-related deaths in children.
![online calcusyn online calcusyn](https://media.springernature.com/lw785/springer-static/image/chp%3A10.1007%2F978-1-61779-080-5_34/MediaObjects/145255_2_En_34_Fig2_HTML.gif)
The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.